C95 COPD ADVANCES IN THERAPY: A Randomized Controlled Trial Of Azd7624, An Inhaled P38 Map Kinase Inhibitor, In COPD Patients On Ics/laba With A History Of Frequent Exacerbations

C95 COPD ADVANCES IN THERAPY: A Randomized Controlled Trial Of Azd7624, An Inhaled P38 Map Kinase Inhibitor, In COPD Patients On Ics/laba With A History Of Frequent Exacerbations

Naimish.Patel@astrazeneca.com Prior study has shown that p38 MAP kinase (MAPK) is upregulated in alveolar macrophages in patients with COPD, and p38 activation increases with COPD severity. Events of rash and elevated liver enzymes that have been associated with oral p38 inhibitors were in infrequen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of respiratory and critical care medicine 2017-01, Vol.195
Hauptverfasser: Make, B J, Patel, N, Cunoosamy, D, Brown, M N, Fageras, M, Lundin, S, Asimus, S, Palmer, R, Taib, Z, Jansson, P, Rennard, S I
Format: Artikel
Sprache:eng
Schlagworte:
Chronic obstructive pulmonary disease
Kinases
Respiratory therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Naimish.Patel@astrazeneca.com Prior study has shown that p38 MAP kinase (MAPK) is upregulated in alveolar macrophages in patients with COPD, and p38 activation increases with COPD severity. Events of rash and elevated liver enzymes that have been associated with oral p38 inhibitors were in infrequent (
ISSN:1073-449X
1535-4970